Shantou SEZ Meiji Pharmaceuticals Co., Ltd.

Main purpose: Using the flurbiprofen gel patch [specification: each patch contains 40 mg of flurbiprofen (area 13.6 cm × 10.0 cm, containing 12 g of paste); trade name: Zepolas®] of the licensed manufacturer MIKASA SEIYAKU CO., LTD as the reference preparation, and the flurbiprofen gel patch [specification: each patch (area 13.6 cm × 10.0 cm) contains 12 g of paste, containing 40 mg of flurbiprofen] developed by Shantou Special Economic Zone Meiji Pharmaceutical Co., Ltd. as the test preparation, the bioequivalence of the two preparations under topical conditions in Chinese healthy subjects was evaluated. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in Chinese healthy subjects; 2) To evaluate the adhesion of the test preparation and the reference preparation during the medication process of Chinese healthy subjects; 3) To evaluate the skin reactivity of the test preparation and the reference preparation to Chinese healthy subjects.

Flurbiprofen gel patch [specification: each patch contains 40 mg of flurbiprofen (area 13.6 cm×10.0 cm, paste content 12 g); trade name: Zepolas®] produced by MIKASA SEIYAKU CO., LTD. was used as the reference preparation, and flurbiprofen gel patch [specification: each patch (area 13.6 cm×10.0 cm) contains 12 g of paste and 40 mg of flurbiprofen] developed by Shantou SEZ Meiji Pharmaceutical Co., Ltd. was used as the test preparation to evaluate the bioequivalence of the two preparations under topical use conditions in Chinese healthy subjects.